World Journal of Cardiology最新文献

{"title":"Prehospital aspirin use is associated with improved clinical outcomes in pulmonary embolism: A retrospective case-control study.","authors":"Mithil Gowda Suresh, Safia Mohamed, Harinivaas Shanmugavel Geetha, Akshaya Sekar, Sushmita Prabhu, Jennifer Sargent, George M Abraham, Juniali Hatwal, Akash Batta, Bishav Mohan","doi":"10.4330/wjc.v17.i11.110178","DOIUrl":"10.4330/wjc.v17.i11.110178","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary embolism (PE) is a leading cause of cardiovascular mortality. Although anticoagulation is the cornerstone of treatment, aspirin's potential to modulate thromboinflammation and improve outcomes in non-surgical PE patients remains underexplored.</p><p><strong>Aim: </strong>To assess whether prehospital aspirin use is associated with improved outcomes in patients hospitalized with acute PE.</p><p><strong>Methods: </strong>We conducted a retrospective case-control study of 323 adult patients admitted with computed tomography-confirmed acute PE from January 2020 to December 2023. Patients were stratified according to documented daily aspirin use for ≥ 7 days prior to hospital admission. Primary outcomes included right ventricular strain, intensive care admission, shock, mechanical ventilation, and in-hospital mortality. Univariate logistic regression was used. A <i>P</i> value < 0.05 was considered significant.</p><p><strong>Results: </strong>Total of 323 patients, 90 (27.9%) used aspirin prehospital. Aspirin users were older (74.2 ± 14.3 years <i>vs</i> 66.9 ± 16.7 years, <i>P</i> < 0.001) and had more coronary artery disease. Aspirin use was associated with significantly lower rates of right ventricular strain on computed tomography [22.2% <i>vs</i> 34.8%, odds ratio (OR) = 0.536, 95% confidence interval (CI): 0.305-0.944, <i>P</i> = 0.029], Intensive care admission (16.7% <i>vs</i> 28.8%, OR = 0.496, 95%CI: 0.266-0.924, <i>P</i> = 0.025), shock (2.2% <i>vs</i> 9.9%, OR = 0.208, 95%CI: 0.048-0.899, <i>P</i> = 0.021), and in-hospital mortality (3.3% <i>vs</i> 11.6%, OR = 0.260, 95%CI: 0.080-0.889, <i>P</i> = 0.022).</p><p><strong>Conclusion: </strong>Prehospital aspirin use is associated with reduced severity and mortality in acute PE. These findings support a potential protective role for aspirin and warrant validation in prospective, multicenter trials.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"17 11","pages":"110178"},"PeriodicalIF":2.8,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12678870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145702072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medium-to-long term outcomes of bioresorbable scaffold treatment in patients with acute coronary syndrome.","authors":"Jun Li, Xin-Rui Li, Mo-Wei Kong, Jie Zhang","doi":"10.4330/wjc.v17.i11.109287","DOIUrl":"10.4330/wjc.v17.i11.109287","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Bioresorbable scaffolds (BRS) are a promising alternative to traditional drug-eluting stents (DES) for the treatment of acute coronary syndrome (ACS). They offer the potential for complete resorption, which may reduce long-term complications such as stent thrombosis and late restenosis. However, the safety, compatibility, and long-term outcomes of BRS in patients with intermediate to low-risk ACS have yet to be thoroughly investigated.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aim: &lt;/strong&gt;To investigate the safety, compatibility, and long-term outcomes of BRS in patients with intermediate to low-risk ACS.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Patients with intermediate to low-risk ACS who underwent percutaneous coronary intervention with either DES or BRS, and were continuously recruited from January 2019 to June 2022 at a single center, were analyzed. Baseline data and clinical follow-up were collected for patients who underwent DES implantation (control group) and BRS implantation (observation group), and the survival outcomes and complications during a maximum follow-up period of 3 years were compared. The primary clinical endpoint was device-oriented composite endpoint (DoCE), representing the occurrence of one of the following events: Cardiac death, stent thrombosis, target vessel myocardial infarction, and clinically driven target lesion revascularization. Secondary endpoints included coronary artery bypass grafting, target vessel revascularization, and non-cardiac death.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 128 patients were included in this study, with an average age of 63 years. Among them, 95 were male (74%). The study involved treatment of 201 blood vessels: 87 (43%) received BRS, and 114 (57%) received DES. A total of 97 patients completed the full 3-year follow-up. During this period, 5 patients (17%) in the observation group and 7 patients (16%) in the control group experienced a major cardiovascular event (DoCE). At the 1-year follow-up, 7 patients (15%) in the observation group and 6 patients (10%) in the control group experienced DoCE, and this difference was statistically significant (&lt;i&gt;P&lt;/i&gt; &lt; 0.05). At the 2-year follow-up, there was also a significant difference between the two groups in the number of patients who needed repeat treatment of the target blood vessel (&lt;i&gt;P&lt;/i&gt; &lt; 0.05). In the observation group, 18 patients (33%) underwent follow-up coronary angiography. During the follow-up period, one patient in the observation group was found to have re-narrowing in the proximal and middle segments of the left anterior descending artery, possibly due to BRS collapse. Another patient in the observation group developed chronic total occlusion in multiple vessels at the 3-year follow-up and underwent coronary artery bypass grafting.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;In low- to intermediate-risk ACS patients, those who got BRS had their first major heart event sooner than those who got DES. BRS is more tissue-friendly, yet","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"17 11","pages":"109287"},"PeriodicalIF":2.8,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12678883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145702085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpreting fractional flow reserve-guided percutaneous coronary intervention <i>vs</i> coronary artery bypass grafting outcomes.","authors":"Heng-Rui Liu, Jie-Ling Weng","doi":"10.4330/wjc.v17.i11.113225","DOIUrl":"10.4330/wjc.v17.i11.113225","url":null,"abstract":"<p><p>Kataveni <i>et al</i>'s meta-analysis offers an important contemporary synthesis of randomized evidence comparing fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass grafting (CABG) in multivessel coronary artery disease (CAD). The pooled analysis found no significant difference in all-cause mortality or stroke, yet CABG was superior in reducing myocardial infarction, major adverse cardiac events, and repeat revascularization. These results confirm CABG's durability even in the era of physiological lesion assessment and second-generation drug-eluting stents. From a traditional Chinese medicine (TCM) perspective, multivessel CAD corresponds to syndromes such as \"heart vessel obstruction\" and \"Qi and blood stagnation\", in which local blockage is compounded by systemic imbalance. While revascularization addresses the structural impediment to blood flow, TCM approaches, including herbal medicine, acupuncture, and lifestyle therapy, aim to improve microcirculation, reduce inflammation, and support recovery, potentially mitigating recurrent ischemic events. This commentary argues that future research should integrate optimal revascularization strategies with rigorously evaluated TCM interventions to address both the anatomical and systemic dimensions of CAD and improve long-term patient outcomes.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"17 11","pages":"113225"},"PeriodicalIF":2.8,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12678889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145701971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of SOX9 in cardiovascular diseases: Evidence today.","authors":"Angat Naresh Chadha, Han Cheng, Jing Yang","doi":"10.4330/wjc.v17.i11.110339","DOIUrl":"10.4330/wjc.v17.i11.110339","url":null,"abstract":"<p><p>SRY-related high-mobility group box 9 (SOX9) is an indispensable transcription factor that regulates multiple developmental pathways related to stem cell differentiation and progenitor cell development. Several studies have investigated the role of SOX9 in chondrogenesis and oncogenesis. Significant research exists describing the role of SOX9 in embryological development of the cardiovascular system. However, there is limited research exploring the roles of SOX9 in development of cardiovascular diseases. In this review we highlight and review the biology and contributions of SOX9 in embryologic cardiac development and shed some light on its participation in the development of myocardial fibrosis, which in turn leads to a wide variety of adverse cardiac outcomes.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"17 11","pages":"110339"},"PeriodicalIF":2.8,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12678890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145702102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Troponin elevation in supraventricular tachycardia: A narrative review.","authors":"Bülent Özlek, Veysel O Tanık, Süleyman Barutçu","doi":"10.4330/wjc.v17.i11.113411","DOIUrl":"10.4330/wjc.v17.i11.113411","url":null,"abstract":"<p><p>Supraventricular tachycardia (SVT) is a frequent cause of emergency presentations. Troponin elevation is common, but its clinical significance remains uncertain and may trigger unnecessary downstream testing. In this mini-review, we aimed to review the prevalence, mechanisms, prognostic relevance, and management of troponin elevation in adult paroxysmal SVT. A narrative review was conducted using PubMed and EMBASE (2000-2025) with MeSH terms related to SVT and troponin. Eligible studies included original research or registry analyses in adults with paroxysmal SVT. Pediatric and atrial fibrillation/flutter cohorts were excluded. Additional data were obtained from reference lists and expert commentaries. Troponin elevation occurs in approximately 30%-50% of adult SVT cases, primarily reflecting a tachycardia-induced supply-demand imbalance or myocardial stretch, rather than plaque rupture. Short-term registry data suggest potential prognostic associations, but long-term outcomes remain inconsistent and are largely determined by comorbidities and underlying coronary artery disease. Troponin-driven management often leads to increased admissions, consultations, and additional testing without a demonstrable benefit. Troponin elevation in SVT is frequent but usually benign. Routine measurement in all patients is not justified. A selective, risk-based approach - focused on ischemic symptoms, electrocardiogram changes, or high-risk clinical features - offers more appropriate, efficient, and patient-centered care.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"17 11","pages":"113411"},"PeriodicalIF":2.8,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12678887/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145702115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Femoral artery plaque: A simple ultrasound clue for severe coronary stenosis.","authors":"Nadezhda G Gumanova, Dmitry K Vasilyev, Alexandre A A Mols, Oxana M Drapkina, Anton R Kiselev","doi":"10.4330/wjc.v17.i11.110899","DOIUrl":"10.4330/wjc.v17.i11.110899","url":null,"abstract":"<p><strong>Background: </strong>With rising angiography costs and risks, we explored whether a 5-minute femoral ultrasound can predict patients that actually require angiography.</p><p><strong>Aim: </strong>To detect associations between atherosclerosis of peripheral arteries and coronary stenosis in patients with coronary heart disease (CHD).</p><p><strong>Methods: </strong>The study included a total of 218 patients (63 ± 10.9 years of age; 54% male) with CHD subjected to coronary angiography and routine diagnostic assessment, including ultrasound imaging to assess the extent of peripheral atherosclerotic lesions. Receiver operating characteristic analysis and binomial logistic regression were used to detect the associations.</p><p><strong>Results: </strong>We demonstrated for the first time that the presence of atherosclerotic plaque with ≥ 70% stenosis in femoral arteries was associated with significant coronary stenosis, with 93% sensitivity and 90% specificity, and thus can be used as an additional diagnostic marker for coronary stenosis. The data indicated associations between femoral artery atherosclerosis and atherosclerotic lesions of coronary arteries, with a high correlation coefficient <i>r</i> = 0.8 (<i>P</i> < 0.05). The presence of an atherosclerotic plaque in the femoral arteries with ≥ 30% or ≥ 70% stenosis was associated with a 30- or 70-fold higher odds ratio of coronary stenosis, respectively.</p><p><strong>Conclusion: </strong>For resource-limited clinics, our findings suggest skipping carotids - femoral ultrasound alone may suffice to rule out severe CHD. Ultrasound imaging femoral artery atherosclerosis provides a simplified approach for patient stratification.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"17 11","pages":"110899"},"PeriodicalIF":2.8,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12678886/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145701951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atrial fibrillation substrate mapping with emphasis on voltage-based guidance.","authors":"Edward J Ciaccio, Henry H Hsia, Hirad Yarmohammadi, Elaine Y Wan, Nicholas S Peters, Deepak Saluja, Angelo B Biviano","doi":"10.4330/wjc.v17.i11.109739","DOIUrl":"10.4330/wjc.v17.i11.109739","url":null,"abstract":"<p><p>Voltage substrate mapping is a promising tool for the treatment of atrial fibrillation (AF). It is helpful to detect atrial fibrosis, which includes areas with low bipolar voltage, heterogeneous conduction properties, and shortened effective refractory period. The voltage amplitude is typically defined as the maximal peak-to-peak level within a specified time window of interest. Contemporary electroanatomic mapping platforms now enable many thousands of data points to be mapped, so that a geometric model of the atrial endocardium is constructable over a short period of time. This mapping procedure is often done with bipolar electrodes to cancel the far-field signal. The recording site coordinates are projected onto an atrial shell, with interpolation of the voltage data across the shell surface. The amplitude of the recorded bipolar electrogram depicted on the three-dimensional shell provides detailed information for substrate mapping. Wherever there are areas of low peak-to-peak voltage, it is thought to mark the presence of abnormal tissue properties and conduction. However, uncontrolled variables and environmental factors affecting voltage level include the oncoming electrical activation wavefront direction, the catheter incidence angle, the force applied to the catheter, and the region-variable shape and structure of atrial tissue. Techniques and settings to acquire atrial voltage data for AF analysis have not been standardized. Methods to characterize atrial electrograms are also presently limited. These factors affect quality and reproducibility of the mapping results. Herein, voltage substrate mapping and its variables pertaining to AF and radiofrequency ablation are described and discussed, with suggestions for future work efforts.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"17 11","pages":"109739"},"PeriodicalIF":2.8,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12678882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145701946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colchicine in coronary artery and cerebrovascular disease: \"Old skin for the new ceremony\".","authors":"Francesco M Animati, Luigi Cappannoli, Simone Proietti, Francesco Fracassi, Rocco A Montone, Carolina Ierardi, Cristina Aurigemma, Enrico Romagnoli, Lazzaro Paraggio, Mattia Lunardi, Francesco Bianchini, Antonio Maria Leone, Carlo Trani, Giovanna Liuzzo, Francesco Burzotta","doi":"10.4330/wjc.v17.i11.110563","DOIUrl":"10.4330/wjc.v17.i11.110563","url":null,"abstract":"<p><p>Colchicine is one of the most widely used drugs in the world. While it is most commonly used in the treatment and prevention of gout, it is also widely used to treat other chronic inflammatory diseases, such as familial Mediterranean fever and Behçet's disease. Regarding cardiovascular disease, an established use of colchicine concerns pericarditis, both acute and chronic, and its effectiveness in this context is supported by multiple studies and robust evidence. Regarding coronary artery disease (CAD), colchicine use has been endorsed in both acute and chronic coronary syndromes (CCS), primarily because of two randomized controlled trials: The COLCOT trial for patients with acute coronary syndromes (ACS) and the LoDoCo2 trial for patients with CCS. Considering this robust evidence, CCS 2024 European Society of Cardiology (ESC) Guidelines recommended 0.5 mg daily colchicine in patients with atherosclerotic CAD to reduce the risk of myocardial infarction, stroke and need for revascularization. However, a few months after the publication of 2024 ESC Guidelines on CCS, the \"CLEAR\" trial demonstrated that among patients who had experienced an acute myocardial infarction, when initiated shortly after the event and continued for a median of 3 years, colchicine did not reduce the incidence of the composite outcome of death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization. This result casts doubt on the indication for colchicine use in ACS and weakens evidence that had previously led to the routine use of colchicine in clinical cardiology practice. This review aims to shed light on the current and past scientific evidence underlying the use of colchicine in ACS, CCS and cerebrovascular disease, and thus seeks to provide a quick yet effective tool for cardiologists facing the long-standing issue of reducing residual inflammatory risk in patients with coronary atherosclerotic disease.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"17 11","pages":"110563"},"PeriodicalIF":2.8,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12678875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145701982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of interatrial shunt treatment for heart failure: A systematic review and meta-analysis.","authors":"Allahdad Khan, Shree Rath, Noor Fatima, Umair Hayat, Prachi Dawer, Hamza Khan, Waseef Ullah, Zahir Ud Din, Alina Sehar, Ibrahim Nagmeldin Hassan","doi":"10.4330/wjc.v17.i10.112001","DOIUrl":"10.4330/wjc.v17.i10.112001","url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF), especially in patients with preserved ejection fraction and mid-range ejection fraction, remains a significant global health burden. Interatrial shunt devices (IASDs), which allow blood flow from the left to the right atrium, offer a novel treatment approach by reducing left atrial pressure and alleviating symptoms.</p><p><strong>Aim: </strong>To evaluate the efficacy and safety of IASDs in patients with HF through a systematic review and meta-analysis.</p><p><strong>Methods: </strong>We performed a systematic review and meta-analysis following Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, analyzing studies up to April 2025. Randomized controlled trials and observational studies comparing interatrial shunt therapy with control groups were included. Data on clinical outcomes were analyzed using Review Manager software.</p><p><strong>Results: </strong>Nine studies involving 1689 patients were included. IASDs significantly improved cardiac output [mean difference (MD): 0.72, 95%CI: 0.13-1.32, <i>P</i> = 0.02], right atrial pressure (RAP) (MD: 0.70, 95%CI: 0.14-1.26, <i>P</i> = 0.01), and 6-minute walk distance (MD: 71.63, 95%CI: 24.13-119.13, <i>P</i> = 0.003). There were no significant differences in major adverse cardiac events, myocardial infarction, ischemic stroke, or new-onset atrial fibrillation. However, all-cause mortality [risk ratio (RR): 1.49, 95%CI: 1.02-2.18, <i>P</i> = 0.04] and cardiovascular death (RR: 1.66, 95%CI: 1.01-2.74, <i>P</i> = 0.05) were significantly higher in the shunt group.</p><p><strong>Conclusion: </strong>IASDs offer significant short-term improvements in cardiac output, RAP, and exercise capacity in HF patients. However, long-term safety concerns, particularly regarding mortality, necessitate further research and careful patient selection.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"17 10","pages":"112001"},"PeriodicalIF":2.8,"publicationDate":"2025-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12576559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiomyopathies of endocrine origin: A state-of-the-art review.","authors":"Jenyfer M Fuentes-Mendoza, Marcio J Concepción-Zavaleta, Juan C Morón-Siguas, Juan M Muñoz-Moreno, Aranza I Pérez-Reyes, Rodrigo Martinez-Galaviz, Raúl D Aguilar-Castañeda, Oziel González-Godoy, Luis A Concepción-Urteaga, José Paz-Ibarra","doi":"10.4330/wjc.v17.i10.111462","DOIUrl":"10.4330/wjc.v17.i10.111462","url":null,"abstract":"<p><p>Endocrine disorders are increasingly recognized as potentially reversible causes of secondary cardiomyopathies, yet they often remain underdiagnosed in clinical practice. These conditions-including thyroid dysfunction, acromegaly, pheochromocytoma, diabetes mellitus, adrenal disorders, among others-can significantly alter cardiac structure and function through hormonal excess, metabolic remodeling, and neurohumoral activation. Hyperthyroidism may lead to high-output heart failure (HF) and atrial fibrillation, while hypothyroidism is associated with diastolic dysfunction, pericardial effusion, and accelerated atherosclerosis. Acromegaly promotes biventricular hypertrophy and myocardial fibrosis <i>via</i> insulin-like growth factor 1 overproduction. Pheochromocytoma triggers catecholamine-induced cardiomyopathy, resembling Takotsubo syndrome and carrying a high risk of mortality if left untreated. Diabetes induces a distinct phenotype of cardiomyopathy, affecting both systolic and diastolic function through microvascular injury and oxidative stress. Recognizing these endocrine etiologies is crucial, as targeted hormonal therapies-such as antithyroid agents, somatostatin analogs, or adrenalectomy-can reverse or significantly mitigate cardiac dysfunction. Comprehensive endocrine screening in patients with unexplained cardiomyopathy is therefore essential. This review synthesizes current knowledge on the pathophysiological mechanisms, clinical manifestations, and therapeutic strategies for endocrine cardiomyopathies and proposes a diagnostic algorithm for early recognition. Emerging biomarkers, such as galectin-3 in diabetic heart disease, may further enhance diagnostic accuracy and risk stratification. The interplay between endocrine and cardiovascular systems offers a unique opportunity for early intervention, potentially preventing progression to irreversible HF.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"17 10","pages":"111462"},"PeriodicalIF":2.8,"publicationDate":"2025-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12576551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}